Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Short-term Investments (2020 - 2024)

Cytek Biosciences' Short-term Investments history spans 4 years, with the latest figure at $29000.0 for Q4 2024.

  • For Q4 2024, Short-term Investments fell 91.24% year-over-year to $29000.0; the TTM value through Dec 2024 reached $29000.0, down 91.24%, while the annual FY2024 figure was $29000.0, 91.24% down from the prior year.
  • Short-term Investments reached $29000.0 in Q4 2024 per CTKB's latest filing, down from $30816.0 in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $2.9 million in Q1 2023 to a low of $29000.0 in Q4 2024.
  • Average Short-term Investments over 4 years is $940727.0, with a median of $365500.0 recorded in 2023.
  • The largest YoY upside for Short-term Investments was 86.29% in 2024 against a maximum downside of 91.24% in 2024.
  • A 4-year view of Short-term Investments shows it stood at $888000.0 in 2020, then skyrocketed by 226.46% to $2.9 million in 2022, then tumbled by 88.58% to $331000.0 in 2023, then tumbled by 91.24% to $29000.0 in 2024.
  • Per Business Quant, the three most recent readings for CTKB's Short-term Investments are $29000.0 (Q4 2024), $30816.0 (Q3 2024), and $30000.0 (Q2 2024).